Quentin B Vincent1, Marie-Françoise Ardant2, Ambroise Adeye2, Aimé Goundote2, Jean-Paul Saint-André3, Jane Cottin4, Marie Kempf4, Didier Agossadou5, Christian Johnson6, Laurent Abel7, Laurent Marsollier8, Annick Chauty2, Alexandre Alcaïs9. 1. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Recherche Médicale U1163 (INSERM), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Paris, France. 2. Centre de Dépistage et de Traitement de l'Ulcère de Buruli (CDTUB), Pobè, Benin; Fondation Raoul Follereau, Paris, France. 3. Laboratoire d'Anatomie Pathologique, CHU d'Angers, Angers, France. 4. Laboratoire de Bactériologie, CHU d'Angers, Angers, France. 5. Programme de Lutte Contre la Lèpre et l'Ulcère de Buruli, Ministère de la Santé, Cotonou, Bénin. 6. Fondation Raoul Follereau, Paris, France. 7. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Recherche Médicale U1163 (INSERM), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA. 8. Institut National de la Recherche Médicale U892 (INSERM) et CNRS U6299, Université et CHU d'Angers, Angers, France. 9. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Recherche Médicale U1163 (INSERM), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA; Unité de Recherche Clinique, Paris Centre Descartes Necker Cochin, Assistance Publique- Hôpitaux de Paris, Paris, France. Electronic address: alexandre.alcais@inserm.fr.
Abstract
BACKGROUND: Buruli ulcer, caused by Mycobacterium ulcerans, was identified as a neglected emerging infectious disease by WHO in 1998. Although Buruli ulcer is the third most common mycobacterial disease worldwide, understanding of the disease is incomplete. We analysed a large cohort of laboratory-confirmed cases of Buruli ulcer from Pobè, Benin, to provide a comprehensive description of the clinical presentation of the disease, its variation with age and sex, and its effect on the occurrence of permanent functional sequelae. METHODS: Between Jan 1, 2005, and Dec 31, 2011, we prospectively collected clinical and laboratory data from all patients with Buruli ulcer diagnosed at the Centre de Dépistage et de Traitement de l'Ulcère de Buruli in Pobè, Benin. We followed up patients to assess the frequency of permanent functional sequelae. All analyses were done on cases that were laboratory confirmed. FINDINGS: 1227 cases of laboratory-confirmed Buruli ulcer were included in the analysis. Typically, patients with Buruli ulcer were children (median age at diagnosis 12 years) presenting with a unique (1172 [96%]) large (≥15 cm, 444 [36%]) ulcerative (805 [66%]) lesion of the lower limb (733 [60%]). Atypical clinical presentation of Buruli ulcer included Buruli ulcer osteomyelitis with no identifiable present or past Buruli ulcer skin lesions, which was recorded in at least 14 patients. The sex ratio of Buruli ulcer widely varied with age, with male patients accounting for 57% (n=427) of patients aged 15 years and younger, but only 33% (n=158) of those older than 15 years (odds ratio [OR] 2·59, 95% CI 2·04-3·30). Clinical presentation of Buruli ulcer was significantly dependent on age and sex. 54 (9%) male patients had Buruli ulcer osteomyelitis, whereas only 28 (4%) of female patients did (OR 2·21, 95% CI 1·39-3·59). 1 year after treatment, 229 (22% of 1043 with follow-up information) patients presented with permanent functional sequelae. Presentation with oedema, osteomyelitis, or large (≥15 cm in diameter), or multifocal lesions was significantly associated with occurrence of permanent functional sequelae (OR 7·64, 95% CI 5·29-11·31) and operationally defines severe Buruli ulcer. INTERPRETATION: Our findings have important clinical implications for daily practice, including enhanced surveillance for early detection of osteomyelitis in boys; systematic search for M ulcerans in osteomyelitis cases of non-specific aspect in areas endemic for Buruli ulcer; and specific disability prevention for patients presenting with osteomyelitis, oedema, or multifocal or large lesions. Our findings also suggest a crucial underestimation of the burden of Buruli ulcer in Africa and raise key questions about the contribution of environmental and physiopathological factors to the recorded heterogeneity of the clinical presentation of Buruli ulcer. FUNDING: Agence Nationale de la Recherche (ANR), Fondation Raoul Follereau, Fondation pour la Recherche Médicale (FRM), and Institut des Maladies Génétiques (IMAGINE).
BACKGROUND:Buruli ulcer, caused by Mycobacterium ulcerans, was identified as a neglected emerging infectious disease by WHO in 1998. Although Buruli ulcer is the third most common mycobacterial disease worldwide, understanding of the disease is incomplete. We analysed a large cohort of laboratory-confirmed cases of Buruli ulcer from Pobè, Benin, to provide a comprehensive description of the clinical presentation of the disease, its variation with age and sex, and its effect on the occurrence of permanent functional sequelae. METHODS: Between Jan 1, 2005, and Dec 31, 2011, we prospectively collected clinical and laboratory data from all patients with Buruli ulcer diagnosed at the Centre de Dépistage et de Traitement de l'Ulcère de Buruli in Pobè, Benin. We followed up patients to assess the frequency of permanent functional sequelae. All analyses were done on cases that were laboratory confirmed. FINDINGS: 1227 cases of laboratory-confirmed Buruli ulcer were included in the analysis. Typically, patients with Buruli ulcer were children (median age at diagnosis 12 years) presenting with a unique (1172 [96%]) large (≥15 cm, 444 [36%]) ulcerative (805 [66%]) lesion of the lower limb (733 [60%]). Atypical clinical presentation of Buruli ulcer included Buruli ulcer osteomyelitis with no identifiable present or past Buruli ulcer skin lesions, which was recorded in at least 14 patients. The sex ratio of Buruli ulcer widely varied with age, with male patients accounting for 57% (n=427) of patients aged 15 years and younger, but only 33% (n=158) of those older than 15 years (odds ratio [OR] 2·59, 95% CI 2·04-3·30). Clinical presentation of Buruli ulcer was significantly dependent on age and sex. 54 (9%) male patients had Buruli ulcer osteomyelitis, whereas only 28 (4%) of female patients did (OR 2·21, 95% CI 1·39-3·59). 1 year after treatment, 229 (22% of 1043 with follow-up information) patients presented with permanent functional sequelae. Presentation with oedema, osteomyelitis, or large (≥15 cm in diameter), or multifocal lesions was significantly associated with occurrence of permanent functional sequelae (OR 7·64, 95% CI 5·29-11·31) and operationally defines severe Buruli ulcer. INTERPRETATION: Our findings have important clinical implications for daily practice, including enhanced surveillance for early detection of osteomyelitis in boys; systematic search for M ulcerans in osteomyelitis cases of non-specific aspect in areas endemic for Buruli ulcer; and specific disability prevention for patients presenting with osteomyelitis, oedema, or multifocal or large lesions. Our findings also suggest a crucial underestimation of the burden of Buruli ulcer in Africa and raise key questions about the contribution of environmental and physiopathological factors to the recorded heterogeneity of the clinical presentation of Buruli ulcer. FUNDING: Agence Nationale de la Recherche (ANR), Fondation Raoul Follereau, Fondation pour la Recherche Médicale (FRM), and Institut des Maladies Génétiques (IMAGINE).
Authors: Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson Journal: Infect Immun Date: 2020-02-20 Impact factor: 3.441
Authors: Carlos Capela; Ghislain E Sopoh; Jean G Houezo; René Fiodessihoué; Ange D Dossou; Patrício Costa; Alexandra G Fraga; João F Menino; Rita Silva-Gomes; Edgard M Ouendo; Fernando Rodrigues; Jorge Pedrosa Journal: PLoS Negl Trop Dis Date: 2015-09-10
Authors: Jianyong Wu; Petra Tschakert; Erasmus Klutse; David Ferring; Vincent Ricciardi; Heidi Hausermann; Joseph Oppong; Erica A H Smithwick Journal: PLoS Negl Trop Dis Date: 2015-06-19
Authors: Marie Robbe-Saule; Mélanie Foulon; Isabelle Poncin; Lucille Esnault; Hugo Varet; Rachel Legendre; Alban Besnard; Anna E Grzegorzewicz; Mary Jackson; Stéphane Canaan; Laurent Marsollier; Estelle Marion Journal: Virulence Date: 2021-12 Impact factor: 5.882
Authors: Daniel P O'Brien; N Deborah Friedman; Raquel Cowan; James Pollard; Anthony McDonald; Peter Callan; Andrew Hughes; Eugene Athan Journal: PLoS Negl Trop Dis Date: 2015-12-02